Remove keyword digital-therapeutics
article thumbnail

Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K. McCreary, PharmD, BCIDP)

Rethinking Clinical Trials

The COVID Therapeutics Committee worked with the state health department to develop a policy for fair allocation of scarce medications to treat COVID-19. The COVID Therapeutics Committee created communication materials to be transparent and to get buy-in. We know there is a digital gap in disadvantaged patients and elderly patients.

article thumbnail

Grand Rounds October 21, 2022: Disinformation, Cyberthreat, and Choice: Protecting Patients and Clinical Research From the Digital Triple Threat (Eric Perakslis, PhD; Andrea Downing)

Rethinking Clinical Trials

Chief Science & Digital Officer. Perakslis said his definition of digital health is any time you mix medical information and the internet. Should social media for teenagers be regulated like a digital therapeutic, given how addictive they are and the behavior modification. Eric Perakslis, PhD. Andrea Downing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI in pharma: Can it be used in DTC?

World of DTC Marketing

Basically, the AI integration monitors social media content around certain keywords and the call center and recommends content be added to the website. DTC marketers can tap into AI to help deliver relevant messages to certain audiences, but they shouldn’t let AI do all their thinking.

Doctors 164
article thumbnail

Grand Rounds March 17, 2023: Remote Symptom Monitoring with Electronic Patient-Reported Outcomes (ePROs) in Oncology (Ethan Basch, MD, MSc)

Rethinking Clinical Trials

Goldberg Distinguished Professor and Chief of Oncology Physician-in-Chief, North Carolina Cancer Hospital Director, Cancer Outcomes Research Program University of North Carolina Slides Keywords Patient-reported outcomes, Oncology, Clinical Trials Key Points Symptoms are common in cancer care. community oncology practices across 25 states.

article thumbnail

Prominent Reasons Behind The Failure Of NAMPT inhibitors And Key Strategies Adopted By Developers To Overcome Such Challenges

Roots Analysis

Despite their potential therapeutic benefits, NAMPT inhibitors have faced several challenges in clinical development. As a starting point, the information on terminated, suspended and withdrawn trials was collated from clinicaltrials.gov and PubMed using relevant search keywords.